Maxalt

Rizatriptan, the active ingredient in Maxalt, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for the acute treatment of migraine attacks, with or without aura, in adult patients. It is prescribed for rapid relief of migraine symptoms and is part of the standard therapeutic options for headache management.

GNH USA supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across European and global markets, supporting healthcare providers with reliable access to this migraine medication.

Rizatriptan is indicated for the acute treatment of migraine, a neurovascular headache disorder mediated by serotonin pathways. - Migraine with aura: provides rapid relief of headache and associated neurological symptoms. - Migraine without aura: reduces pain intensity and duration when taken at onset. - Acute migraine attacks: aborts the attack and improves functional ability within hours of administration.

Rizatriptan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Tingling or numbness: transient paresthesia in fingers or lips. - Dizziness: mild light‑headedness, often resolves quickly. - Fatigue: feeling of tiredness or weakness. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Chest discomfort: may indicate cardiac ischemia and requires immediate evaluation. - Serotonin syndrome: rare but potentially life‑threatening reaction when combined with other serotonergic agents. - Severe allergic reaction: hives, swelling, or difficulty breathing. - Visual disturbances: blurred vision or visual field changes.

When prescribing Rizatriptan, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: avoid in patients with uncontrolled coronary artery disease or recent myocardial infarction. - Medication history: review use of other serotonergic drugs to reduce risk of serotonin syndrome. - Age limitation: not recommended for children under 12 years of age. - Hepatic/renal function: dose adjustment may be needed in severe impairment. - Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with obstetrician. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Rizatriptan can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate serotonin syndrome. - Ergot alkaloids: combined use increases risk of vasospasm and severe vasoconstriction. - Other triptans: additive vasoconstrictive effects, avoid co‑administration. - SSRIs/SNRIs: may raise serotonin levels, heightening serotonin syndrome risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can increase rizatriptan plasma concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Antihypertensives: monitor blood pressure as vasoconstriction may potentiate effects.